cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Vaxcyte Inc
2 own
3 watching
Current Price
$61.6
$0.77
(1.27%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
6,217.12M
52-Week High
52-Week High
82.04000
52-Week Low
52-Week Low
41.57000
Average Volume
Average Volume
0.61M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization6,217.12M
icon52-Week High82.04000
icon52-Week Low41.57000
iconAverage Volume0.61M
iconDividend Yield--
iconP/E Ratio--
What does the Vaxcyte Inc do?
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Read More
How much money does Vaxcyte Inc make?
News & Events about Vaxcyte Inc.
TipRanks Financial Blog
10 months ago
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT Research Report), Int... Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT Research Report), Intercept...
Globe Newswire
1 year ago
SAN CARLOS, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of ...
PR Newswire
1 year ago
Thinking about buying stock in CNS Pharmaceuticals, Revelation Biosciences, Oblong, Vaxcyte, or Peabody Energy? Thinking about buying stock in CNS Pharmaceuticals, Revelation Biosciences, Oblong, Vaxcyte, or Peabody Energy? PR Newswire NEW YORK, April 17, 2023 NEW YORK, April 17, 2023 /PRNewswire...
Ticker Report
1 year ago
Vaxcyte (NASDAQ:PCVX Get Rating) had its price objective reduced by Guggenheim from $66.00 to $65.00 in a report released on Tuesday , Benzinga reports. They currently have a buy rating on the stock. PCVX has been the topic of several other research reports. SVB Leerink reiterated an ...
Ticker Report
1 year ago
Vaxcyte (NASDAQ:PCVX Get Rating) had its price target decreased by Guggenheim from $66.00 to $65.00 in a report published on Tuesday, Benzinga reports. Guggenheim currently has a buy rating on the stock. Several other brokerages have also commented on PCVX. BTIG Research started coverage on ...
Frequently Asked Questions
Frequently Asked Questions
What is Vaxcyte Inc share price today?
plus_minus_icon
Can Indians buy Vaxcyte Inc shares?
plus_minus_icon
How can I buy Vaxcyte Inc shares from India?
plus_minus_icon
Can Fractional shares of Vaxcyte Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Vaxcyte Inc stocks?
plus_minus_icon
What is today’s traded volume of Vaxcyte Inc?
plus_minus_icon
What is today’s market capitalisation of Vaxcyte Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Vaxcyte Inc?
plus_minus_icon
What percentage is Vaxcyte Inc down from its 52-Week High?
plus_minus_icon
What percentage is Vaxcyte Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$61.6
$0.77
(1.27%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00